Visible Genetics' HIV resistance testing software:
This article was originally published in Clinica
Visible Genetics has received US FDA 510(k) clearance to market its next-generation HIV resistance interpretation software for use with its TRUGENE HIV-1 genotyping test. The GuideLines 5.0 Rules software includes the latest data on HIV drug resistance, including information on the newly launched HIV drugs, tenofovir and lopinavir/ritonavir. The HIV virus is constantly evolving and it is critical that HIV resistance testing is conducted using technology that is both fully validated and up-to-date, says the Toronto, Canada firm.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.